Journal article
A phase i clinical trial of dendritic cell immunotherapy in HCV-infected individuals
EJ Gowans, S Roberts, K Jones, I Dinatale, PA Latour, B Chua, EMY Eriksson, R Chin, S Li, DM Wall, RL Sparrow, J Moloney, M Loudovaris, R Ffrench, HM Prince, D Hart, W Zeng, J Torresi, LE Brown, DC Jackson
Journal of Hepatology | ELSEVIER SCIENCE BV | Published : 2010
Abstract
Background & Aims: HCV patients who fail conventional interferon-based therapy have limited treatment options. Dendritic cells are central to the priming and development of antigen-specific CD4+ and CD8+ T cell immunity, necessary to elicit effective viral clearance. The aim of the study was to investigate the safety and efficacy of vaccination with autologous dendritic cells loaded with HCV-specific cytotoxic T cell epitopes. Methods: We examined the potential of autologous monocyte-derived dendritic cells (MoDC), presenting HCV-specific HLA A2.1-restricted cytotoxic T cell epitopes, to influence the course of infection in six patients who failed conventional therapy. Dendritic cells were l..
View full abstractGrants
Funding Acknowledgements
This study was supported by grant number RO1 A1054459 from the National Institutes of Health, USA and by donations from Perpetual Finance Pty, Sydney, Australia. MiltenyiBiotec supplied the CliniMACS instrument for the duration of the study.